We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New COVID-19 Test Combines AI and Nanopore Technology to Detect SARS-CoV-2 at POC in Five Minutes

By LabMedica International staff writers
Posted on 18 Jun 2021
Researchers have developed a new highly sensitive test for the SARS-CoV-2 virus that utilizes a fusion of artificial intelligence (AI) and nanopore technology which may enable rapid point-of-care testing for COVID-19.

A team of scientists at Osaka University (Osaka, Japan) have demonstrated that single virus particles passing through a nanopore could be accurately identified using machine learning. More...
The test platform they created was so sensitive that the coronaviruses responsible for the common cold, SARS, MERS, and COVID could be distinguished from each other. This work may lead to rapid, portable, and accurate screening tests for COVID and other viral diseases.

The global coronavirus pandemic has revealed the crucial need for rapid pathogen screening. However, the current gold-standard for detecting RNA viruses - including SARS-CoV-2, the virus that causes COVID - is reverse transcription-polymerase chain reaction (RT-PCR) testing. While accurate, this method is relatively slow, which hinders the timely interventions required to control an outbreak. Now, scientists led by Osaka University have developed an intelligent nanopore system that can be used for the detection of SARS-CoV-2 virus particles. Using machine-learning methods, the platform can accurately discriminate between similarly sized coronaviruses responsible for different respiratory diseases.

To fabricate the device, nanopores just 300 nanometers in diameter were bored into a silicon nitride membrane. When a virus was pulled through a nanopore by the electrophoretic force, the opening became partially blocked. This temporarily decreased the ionic flow inside the nanopore, which was detected as a change in the electrical current. The current as a function of time provided information on the volume, structure, and surface charge of the target being analyzed. However, to interpret the subtle signals, which could be as small as a few nanoamps, machine learning was needed. The team used 40 PCR-positive and 40 PCR-negative saliva samples to train the algorithm.

Using this platform, the researchers were able to achieve a sensitivity of 90% and a specificity of 96% for SARS-CoV-2 detection in just five minutes using clinical saliva samples. The complete test platform consists of machine learning software on a server, a portable high-precision current measuring instrument, and cost-effective semiconducting nanopore modules. By using a machine-learning method, the researchers expect that this system can be adapted for use in the detection of emerging infectious diseases in the future. The team hopes that this approach will revolutionize public health and disease control.

"Our innovative technology has high sensitivity and can even electrically identify single virus particles," said first author Professor Masateru Taniguchi. "We expect that this research will enable rapid point-of-care and screening tests for SARS-CoV-2 without the need for RNA extraction. A user-friendly and non-invasive method such as this is more amenable to immediate diagnosis in hospitals and screening in places where large crowds are gathered."

Related Links:
Osaka University


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.